


IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 13 NO 2 JUNE 1996

ISSN 0790-9667





Good Night and Good Morning

Striking the balance between short and long acting hypnotics, Noctamid allows your patients to get a good night's sleep, and get the most out of their day. ¹

Presentation Tablets containing 0.5mg or 1mg lormetazepam. **Uses** Short-term treatment of insomnia which is disabling or causing extreme distress. **Dosage and administration** *Adults only:* 0.5mg - 1mg. *Elderly:* 0.25-0.5mg. Duration of use should be as short as possible. Dosage should be decreased progressively. **Contraindications** Myasthenia gravis, hypersensitivity to benzodiazepines, severe respiratory or hepatic insufficiency, sleep apnoea syndrome, acute intoxication with alcohol, hypnotics, analgesics or psychotropic drugs. **Precautions and warnings** Not for use in patients under 18 years. Use only with great caution in renal or hepatic insufficiency, the elderly, debilitated, in chronic pulmonary insufficiency or with history of alcohol or drug abuse. Abrupt termination of treatment may be accompanied by withdrawal symptoms. Risk of tolerance, dependence, rebound insomnia

and anxiety, amnesia, psychiatric and paradoxical reactions (discontinue treatment). Not for primary treatment of psychotic illness or for use alone in depression. Depression must be ruled out. Pre-existing depression may be unmasked and suicide precipitated. Avoid concomitant intake with alcohol. Enhancement of the effect may occur with CNS depressants and hepatic enzyme inhibitors. Do not use during pregnancy, delivery and lactation. May

adversely affect ability to drive or use machines. **Side-effects** Drowsiness during the day, numbed emotions, reduced alertness, confusion, fatigue, headache, dizziness, muscle weakness, ataxia, double vision, gastrointestinal disturbances, changes in libido, skin reactions, anterograde amnesia. Further information available on request from PA Holder: HE Clissmann, 44 Dartmouth Square, Dublin 6. Tel 01-6688566 Fax 01-680 4957. **Package quantities** 30x0.5mg tablets (PA 12/51/1 GMS No. 36811) 30x1mg tablets (PA 12/51/2 GMS No. 36838) 100x1mg tablets (PA 12/51/2 GMS No. 36854). **References:** 1. Hindmarch, I., The subjective evaluation of sleep, Proceedings of an International Symposium: Benzodiazepines, Sleep and Daytime Performance, Amsterdam 1983, published by The Medicine Publishing Foundation, Oxford, 1983. U.Text 2709, 2/96.

Noctamid
lormetazepam

Editor-in-Chief: Brian Lawlor

Editorial Assistant: Niamh Gleeson

Advertising Manager: Frank Corr

Editors: Timothy Dinan (London),
David King (Belfast)

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaithe (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)

Statistical Editor: Leslie Daly (Dublin)

Deputy Statistical Editor:
Ronan Conroy (Dublin)

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.

Telephone
01-2803967; Int: +353-1-2803967

Fax
01-2807076; Int: +353-1-2807076

Publisher
MedMedia Ltd.
Media House,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.

Printing: New Cityview Press

Subscriptions
Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU, US\$96 USA, STG£53
elsewhere (single issues US\$28 USA,
STG£13.25 elsewhere) incl. airmail
postage internationally.

**Subscription enquiries, orders
and cheques made payable to:**
Royal Society of Medicine Services Ltd.,
1 Wimpole St,
London, W1M 8AE, UK.
Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.

Circulation
3,000 to 54 countries.
Journal participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health.
Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.

EDITORIAL

- 46 **Chronic fatigue syndrome**
John Joyce, Simon Wessely

ORIGINAL PAPERS

- 51 **Dementia in an Irish population of Down's syndrome people**
Janette F Tyrrell, Mary P Cosgrave, Martin McLaughlin, Brian A Lawlor
- 55 **Memory impairment in Alzheimer's disease: replication and extension of the delayed word recall (DWR) test**
Robert F Coen, Gregory RJ Swanwick, Conor Maguire, Michael Kirby, Brian A Lawlor, J Bernard Walsh, D Coakley

BRIEF REPORTS

- 59 **Observations of the observed: a study of inpatients' perceptions of being observed**
SR Moorhead, M Langenbach, J Kennedy, CM Hodgson, P Ruiz, O Junaid
- 62 **Benzodiazepine misuse and dependence among opiate addicts in treatment**
Hugh Williams, A Oyefeso, AH Ghodse

AUDITS

- 65 **The attitude of general practitioners in North-West England to patients with schizophrenia**
John Holden

REVIEWS

- 67 **Eating psychopathology and its effect on pregnancy, infant growth and development**
Fiona McNicholas

CASE REPORTS

- 70 **Delusional misidentification syndromes in a woman with mild learning disabilities**
Sally-Ann Cooper, Richard A Collacott
- 72 **A case of Koro in a 20 year old Irish male**
John Tobin
- 74 **A failed suicide pact**
S Amin, K Fisher
- 75 **Punch drunk syndrome**
AK Upadhyaya, L Kilshaw, RS Dyal
- 77 **Bipolar affective disorder and autoimmune disease**
Sadgun Bhandari

HISTORICAL

- 79 **In search of black bile**
Brian E Leonard
- 54 **Guidelines for authors**
- 73 **John Dunne Medal**
- 83 **Letters to the editor**

Cover illustration: 'The Sunshade', William Leech (circa 1911)

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST/PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

REASON TO BE CHEERFUL



LUSTRALTM 50mg

sertraline



Established in treating depression



Abbreviated Prescribing Information
LUSTRALTM Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to Lustral. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with,

MAOI's. At least 7 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, Warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia.

Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 19/46/4) Calendar pack of 28; 100mg tablet (PA 19/46/5) Calendar pack of 28. Further information on request. **InvictaTM Pharmaceuticals.** A Division of Pfizer Limited, Sandwich, Kent. Agents in Ireland: Cahill May Roberts, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland

